HCA Healthcare (NYSE:HCA) Releases Earnings Results, Beats Expectations By $0.53 EPS

HCA Healthcare (NYSE:HCA) issued its quarterly earnings results on Tuesday. The company reported $5.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.97 by $0.53, Briefing.com reports. The company had revenue of $17.49 billion for the quarter, compared to the consensus estimate of $17.05 billion. HCA Healthcare had a return on equity of 621.57% and a net margin of 8.40%. HCA Healthcare’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the business posted $4.29 earnings per share. HCA Healthcare updated its FY 2024 guidance to 21.600-22.800 EPS.

HCA Healthcare Stock Up 1.1 %

NYSE:HCA opened at $343.94 on Thursday. The stock’s fifty day moving average is $328.88 and its two-hundred day moving average is $322.41. HCA Healthcare has a 52 week low of $215.96 and a 52 week high of $348.00. The company has a quick ratio of 1.02, a current ratio of 1.16 and a debt-to-equity ratio of 29.26. The stock has a market capitalization of $90.08 billion, a price-to-earnings ratio of 17.15, a price-to-earnings-growth ratio of 1.45 and a beta of 1.68.

HCA Healthcare Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, September 30th. Investors of record on Monday, September 16th will be given a dividend of $0.66 per share. The ex-dividend date of this dividend is Monday, September 16th. This represents a $2.64 dividend on an annualized basis and a dividend yield of 0.77%. HCA Healthcare’s payout ratio is currently 13.16%.

Insider Buying and Selling

In other news, SVP Kathryn A. Torres sold 1,863 shares of the stock in a transaction dated Wednesday, May 15th. The shares were sold at an average price of $326.18, for a total transaction of $607,673.34. Following the sale, the senior vice president now owns 19,612 shares of the company’s stock, valued at $6,397,042.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, SVP Kathryn A. Torres sold 1,863 shares of the stock in a transaction on Wednesday, May 15th. The stock was sold at an average price of $326.18, for a total value of $607,673.34. Following the sale, the senior vice president now directly owns 19,612 shares in the company, valued at $6,397,042.16. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Kathryn A. Torres sold 973 shares of the company’s stock in a transaction dated Thursday, May 2nd. The stock was sold at an average price of $312.00, for a total value of $303,576.00. Following the sale, the senior vice president now owns 22,365 shares in the company, valued at approximately $6,977,880. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 12,397 shares of company stock valued at $3,921,929. Corporate insiders own 1.60% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have issued reports on HCA shares. TD Cowen decreased their price objective on shares of HCA Healthcare from $371.00 to $360.00 and set a “buy” rating on the stock in a report on Tuesday, April 30th. Royal Bank of Canada increased their target price on HCA Healthcare from $329.00 to $378.00 and gave the company an “outperform” rating in a report on Wednesday. JPMorgan Chase & Co. increased their price objective on HCA Healthcare from $327.00 to $332.00 and gave the company a “neutral” rating in a research note on Thursday, May 30th. Wells Fargo & Company upped their target price on shares of HCA Healthcare from $303.00 to $315.00 and gave the stock an “equal weight” rating in a report on Thursday, March 28th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $335.00 price objective on shares of HCA Healthcare in a research note on Wednesday. Four investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, HCA Healthcare presently has a consensus rating of “Moderate Buy” and a consensus target price of $339.72.

About HCA Healthcare

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.